BACKGROUND: Data on the cost-effectiveness of the behavioral treatment of obesity are not conclusive. The cost-effectiveness of treatment in primary care settings is particularly relevant. METHODS: We conducted a within-trial cost-effectiveness analysis of a primary care-based obesity intervention. Study participants were randomized to: Usual Care (UC; quarterly visits with their primary care provider); Brief Lifestyle Counseling (BLC; quarterly provider visits plus monthly weight loss counseling visits) or Enhanced Brief Lifestyle Counseling (EBLC; all above interventions, plus choice of meal replacements or weight loss medication). A health-care payer perspective was used. Intervention costs were estimated from tracking data obtained prospectively. Quality-adjusted life years (QALYs) were estimated with the EuroQol-5D. We estimated cost per kilogram-year of weight loss and cost per QALY. RESULTS: Weight losses after 2 years were 1.7, 2.9 and 4.6 kg for UC, BLC and EBLC, respectively (P ¼ 0.003 for comparison of EBLC vs UC). The incremental cost per kilogram-year lost was $292 for EBLC compared with UC (95% confidence interval (CI): $219-$437). The short-term incremental cost per QALY was $115 397, but the 95% CI were undefined. Comparison of short-term cost per kg with published estimates of longer-term cost per QALY suggested that the intervention could be cost-effective over the long term (X10 years). CONCLUSIONS: A primary care intervention that includes monthly counseling visits and a choice of meal replacements or weight loss medication could be a cost-effective treatment for obesity over the long term. However, additional studies are needed on the cost-effectiveness of behavioral treatment of obesity.
INTRODUCTION
Obesity accounts for over 9% of health-care expenditures in the United States 1 and is one of the leading causes of disability. 2 There is an increased focus on treating obesity in primary care settings, [3] [4] [5] which is highlighted by the recent decision from the Centers for Medicare and Medicaid Services to reimburse providers for intensive behavioral weight loss counseling conducted in primary care settings. 6 A sizeable body of evidence supports the clinical efficacy of obesity treatment, [7] [8] [9] but the cost-effectiveness of non-surgical treatment remains a partially open question. For example, two groups of investigators conducted economic analyses of the Diabetes Prevention Program (DPP) and arrived at different conclusions about the cost-effectiveness of the intervention. [10] [11] [12] Questions regarding the cost-effectiveness of treatment are particularly relevant to primary care settings, given the potentially higher costs of conducting treatment in health-care environments, in contrast to programs that use lay personnel to deliver weight loss interventions.
We conducted an economic analysis of a clinical trial of obesity treatment that was implemented in six primary care practices. The study showed that quarterly primary care provider (PCP) visits in conjunction with brief monthly counseling visits provided by a medical assistant, combined with either meal replacements or weight loss medication, produced greater weight loss than did quarterly PCP visits alone. 13 
MATERIALS AND METHODS Participants
The clinical trial Practice-based Opportunities for Weight Reduction (POWER) at the University of Pennsylvania (POWER-UP) was a randomized comparison of three interventions, conducted in six primary care practices owned by the University of Pennsylvania Health System. 13 Study participants (n ¼ 390) had a body mass index of 30-50 kg m À 2 , weight of p182 kg, plus abdominal obesity (elevated waist circumference) and at least one of the four other criteria for metabolic syndrome-impaired fasting glucose/diabetes, elevated blood pressure/hypertension, low high-density lipoprotein cholesterol or elevated triglycerides.
14 Participants also had no serious or lifethreatening medical conditions. The methods for POWER-UP 13 and two related trials 15, 16 have been described in detail previously. 17 In POWER-UP, participants assigned to Usual Care (UC; n ¼ 130) received weight loss advice during quarterly visits with their PCP. Participants assigned to Brief Lifestyle Counseling (BLC; n ¼ 131) received quarterly visits with their PCP, as well as brief monthly counseling visits with a weight loss coach, who was typically a medical assistant from the practice. Participants assigned to Enhanced Brief Lifestyle Counseling (EBLC; n ¼ 129) received quarterly PCP visits, monthly coaching visits, as well as a choice of 'enhanced' therapy-either meal replacements (Slim-Fast) or weight loss medication (orlistat or sibutramine; sibutramine was removed from the US market in October 2010, toward the end of POWER-UP).
Design of cost-effectiveness analysis
We conducted an economic analysis to assess the cost-effectiveness of all three interventions (UC, BLC and EBLC). All resource use and other outcome data (for example, weight data and quality-adjusted life years (QALYs)) for the economic analysis were collected prospectively. All 390 individuals from the clinical trial contributed data to the cost-effectiveness analysis.
Time horizon
The time horizon for the study was the 2 years that each participant was enrolled in the trial (that is, within-trial cost-effectiveness). All costs, kilogram-years and QALYs during the second year were discounted at 3%.
Perspective
We took both a narrow health-care payer perspective, which included all costs attributable to the intervention, and a broader health-care payer perspective that added the costs of concomitant medications and estimates of participants' other health-care use. The broader payer perspective was included to assess whether costs incurred for the intervention would be offset by reductions in other health-care utilization.
Outcome measures and data sources
Intervention costs. We estimated the costs of the various components of the intervention including weight loss visit costs (primary care physicians plus coaches), weight loss medications, weight loss meal replacements, primary care physician training and supervision, coach training and supervision, and other intervention costs (for example, pedometers, scales).
Concomitant medication and other health-care costs. Concomitant medication use was assessed by reviewing medication lists with patients. Concomitant medication use also was confirmed through review of medical records. Other health-care use was assessed with a questionnaire that asked about visits to physicians, visits to other health-care providers, emergency room visits and hospitalizations. We assigned costs to medications by use of the 'Big 4' Federal Supply Schedule, the pharmaceutical price list used by the Coast Guard, the Department of Defense, the Public Health Service and the Veterans Administration. 18 Costs of other health-care use were assigned using cost schedules from publicly available sources, following the methods used in the economic evaluation of the DPP. 19 All costs were updated to 2011, the year in which the trial concluded. 20 Weight loss. Certified staff members used a digital scale (Tanita BWB-800) to measure weight at baseline and at 6, 12, 18 and 24 months. 13 QALYs. We used the EuroQoL (EQ5D) 3-level health state classification system and scoring rule to assess QALYs. 21 One QALY represents one year of life lived in perfect health, whereas zero represents death.
Cost per kilogram-year and cost per QALY. We estimated three ratios comparing the incremental cost of the weight loss intervention per incremental kilogram-year of weight loss during the two years of the trial, one ratio each for the three pairwise comparisons (BLC vs UC, EBLC vs UC, and EBLC vs BLC). The cost per kilogram-year is defined as the cost of losing 1 kg of weight for one year. Incremental kilogram-years were calculated as the difference in the area under the kilogram loss curves. One reason our primary ratios report on changes in kilograms instead of changes in QALYs is that the primary benefits of weight loss are related to avoided long-term disability and death and are unlikely to be observable in a 2-year study. The primary reason for using kilogram-years of weight loss (similar to pack years in smoking) rather than kilograms or pounds lost as the measure of change in weight is to standardize the results across studies with different lengths of follow-up. 22 , 23 Had we not standardized, our ratio would reflect 2 years of costs divided by the mean weight reduction during the 2 years. The resulting ratio would not be comparable with ratios from single-year studies that reflect 1 year of costs and possibly the same number of kilograms lost in year 1. In addition, we calculated a second set of ratios that expanded the numerator to include concomitant medication and other health-care costs. We also calculated two sets of ratios with these same numerators but with incremental QALYs as the denominator.
Analysis
Cost data. We separately performed multivariable analysis on five different types of costs: weight loss visits; weight loss medications; meal replacements; concomitant medications and other health-care costs. (We allocated mean PCP training costs, lifestyle coach training costs and other intervention costs without use of multivariable analysis.) With the exception of weight loss visit costs (for which everyone had a non-zero cost), we estimated costs by use of two-part multivariable models (that is, first part logit models to estimate the probability that the participant had any costs; second part generalized linear models to estimate non-zero costs). Selection of link functions and families for the generalized linear models was guided by the fit of the data. 24 Weight loss. We followed the analysis of weight loss performed for the clinical trial and used a linear mixed-effects model. QALY scores. Between 10 and 40% of QALY scores were missing at the different follow-up time points. We addressed missing data by the use of inverse probability weighting in the logistic regression as first part models and the generalized linear model as second part models that we developed to predict these scores. 25, 26 Weights were defined as the reciprocal of the estimated probability of being observed (that is, generated from logistic regression with 'missing' status as the dependent variable). QALYs were calculated as the area under the discounted QALY score curve.
Sampling uncertainty. Standard errors were estimated by the use of a non-parametric bootstrap within the multivariable framework. We combined data on point estimates and standard errors to calculate P-values for the point estimates, 95% confidence intervals (CIs) for the cost-effectiveness ratios and the fraction of the distribution of the costeffectiveness ratios that was acceptable at thresholds of $300 and $400 per kilogram-year and at thresholds of $10 000 and $200 000 per QALY. 24 We also plotted the distribution of the cost-effectiveness ratio on the costeffectiveness plane and illustrated the point estimate and 95% CIs for the comparisons of BLC vs UC and EBLC vs UC.
Long-term cost per QALY or per life year gained. We did not directly project costs, weight losses or QALYs beyond 2 years of follow up. However, we attempted to put our within-trial cost-effectiveness ratios into perspective by comparing our weight loss intervention cost per kilogram-year of weight loss ratios with those of published studies that reported both a within-trial weight loss intervention cost per kilogram (or kilogram-year) lost ratio (or the data from which such a ratio can be calculated) and a long-term cost per year of life saved or per QALY ratio.
RESULTS

Characteristics of study participants
Baseline characteristics of study participants and weight losses are shown in Table 1 . Participants were mostly female, and the majority were non-Hispanic white. They took an average of 3.3 medications and had an average of 2.4 self-reported medical conditions. At 1 year, participants assigned to EBLC lost significantly more weight than those in either of the other two groups. After 2 years, those in EBLC lost significantly more weight than those assigned to UC, but not significantly more than those assigned to BLC.
Costs, kilogram-years and QALYs Costs, kilogram-years of weight loss and QALYs are shown in Table 2 . Intervention costs were highest for EBLC ($3092), followed by BLC ($1323) and by UC ($837; with all P-valueso0.05). UC had significantly higher concomitant medication costs than did EBLC, with BLC not significantly different from the other two groups. There were no significant differences between the three groups' other health-care costs. Mirroring the patterns for intervention cost, kilogram-years of weight loss were highest for EBLC followed by BLC and then by UC (all differences statistically significant). There were no significant differences between the three groups' QALYs.
Incremental costs and outcomes, cost-effectiveness ratios and acceptability cutoffs Table 3 shows the incremental costs, kilogram-years of weight loss and QALYs, as well as incremental cost-effectiveness ratios and their 95% CI, and the percentage of the distribution of the incremental cost-effectiveness ratio that was acceptable (that is, below a cutoff that should be acceptable to health-care payers). Ratios of incremental intervention costs to incremental kilogramyears of weight loss ranged from $201 (BLC vs UC) to $333 (EBLC vs BLC). Thus, if health-care payers are willing to pay $300 per kilogram-year, there was between a 56 and 75% chance that either BLC or EBLC was cost-effective, relative to UC. If payers are willing to pay $400 per kilogram-year, there was a 84-95% chance that either BLC or EBLC was cost-effective.
When the analytic approach switched from kilogram-years of weight loss to within-trial QALYs, there was limited evidence that either BLC or EBLC was cost-effective relative to UC. The point estimate for QALYs for BLC was smaller than that for UC (yielding a point estimate for the comparison of costs and effects that indicated that BLC was dominated-more costly and less effective-by UC). Only 20% of the distribution of the resulting cost-effectiveness ratio indicated that BLC was acceptable. The ratios for EBLC vs UC were both greater than $100 000 per QALY, with at most 47% of the distribution acceptable (EBLC vs UC with willingness to pay of $200 000 per QALY). Figures 1 and 2 show the bootstrap distributions of the difference in cost and effect plus the point estimates (large black circles) and 95% CIs (dashed lines) of the cost-effectiveness ratio for kilogram-years ( Figure 1 ) and for short-term QALYs (Figure 2 Table 4 reports the results of four studies, which reported (or from which we were able to estimate) a cost per kilogram or per kilogram-year as well as a longer term cost per QALY or per life year gained. 19, [27] [28] [29] [30] [31] Our estimates of $201, $292 and $333 weight e This estimate is for the total number of quality-adjusted life years (QALYs) over the 2 years of the trial; the range of possibly QALYs is 0 (worst health) to 2 (perfect health).
loss intervention costs per kilogram-year ratios generally fall at the upper end of the cost per kilogram range for these studies. Assuming that the relationship between short-term cost per kilogram and long-term cost per QALY observed in these studies is also applicable to our ratio, we would expect that our long-term cost per QALY ratio for BLC vs UC would fall somewhere in the range between $7 000 and $12 600, and for EBLC vs UC the cost per QALY might be as high as $22 000. Even if the relationship between our cost per QALY and cost per kilogram lost ratios was twice that in the other studies, our point estimate would be less than $26 000 (BLC vs UC) and $44 000 (EBLC vs UC) per QALY.
DISCUSSION
In this study, the within-trial estimate of cost per kilogram was similar to other studies. 19, [27] [28] [29] [30] [31] [32] [33] [34] The within-trial estimates of cost per QALY, on the other hand, did not suggest that the BLC and EBLC interventions were cost-effective, relative to UC. As the ultimate benefits of weight loss are the avoidance of long-term disability and death, we did not expect the latter ratios to be acceptable. Our comparison of published cost per kilogram ratios with their projected long-term cost per QALY ratios suggests that, had we used a decision model to project our results, they would have fallen in an acceptable range. Thus, if health-care payers are willing to base health policy on the results of decision models, the POWER-UP results suggest that a primary care-based treatment model could be cost-effective over the long term.
CIs for the short-term cost per QALY ratios could not be estimated with precision. The BLC and EBLC interventions were more expensive than the UC intervention, but these costs were somewhat offset by lower costs for concomitant medications, as shown in other trials. [35] [36] [37] The most robust long-term estimate of cost per QALY comes from the DPP, and suggests that intensive behavioral intervention is cost-effective over the longer term (10 years to lifetime). 27 Most other cost-effectiveness studies of obesity treatment also have reported cost-effectiveness ratios of less than $50 000 per QALY. 29, 30, [38] [39] [40] [41] [42] [43] The ongoing economic analysis of the Look AHEAD (Action for HEAlth in Diabetes) Trial will provide more data about the cost-effectiveness of intensive obesity treatment. A preliminary estimate of cost per kilogramyear, using cost data presented as an abstract 44 and 4-year weight losses from Look AHEAD, 45 suggests that the cost of that intervention may be higher (approximately $300 per kilogramyear) than in the DPP.
A major question underlying economic analyses of health-care interventions is: will payers reimburse them? With regard to obesity, treatment has historically been inconsistently reimbursed or not reimbursed at all. The recent decision by Medicare to reimburse intensive treatment in primary care is welcome, although evaluation of effectiveness will certainly be needed. Reimbursement for obesity treatment in all forms has often been The CIs for the weight loss intervention cost per QALY CIs and weight loss and other health-care cost per QALY represent exclusion intervals. We can be 95% confident of value when our willingness to pay falls outside the CI. For example, if willingness to pay is greater than -$55 374 and less than $33 395, then we can be 95% confident that compared with UC, the EBLC intervention yields QALYs at a weight loss intervention cost that exceeds our willingness to pay. Otherwise, we cannot be 95% confident that the value of the two therapies differs.
b When the 95% CI is undefined, there is no value of willingness to pay for which we can be 95% confident that the intervention provides units of outcome (for example, QALYs) at a price that is below our willingness to pay. This occurs when cost-effectiveness ratios fall into all four quadrants of the cost-effectiveness plane.
subjected to a 'return on investment' argument-that is, treatment must save the employer or health plan money in order to be reimbursed. Although some evidence suggests that employer-sponsored wellness programs can produce a return on investment, 46 only a minority of health-care interventions are actually cost saving. 47 With obesity treatment, the return on investment is likely to take longer to observe than most payers are able or willing to wait. 48 An alternative approach to obesity coverage decisions, which is used by the National Institute for Clinical Excellence (NICE) in the United Kingdom, is to subject all new treatments to analyses of clinical and cost-effectiveness. Orlistat, a pharmacologic treatment for obesity, underwent such an analysis, and despite the modest weight losses associated with the drug, was recommended by NICE to be used in clinical practice. 49 A major goal of health services research in obesity is to help determine how obesity prevention and treatment can be delivered to the largest number of people at the lowest possible cost. The results of this analysis suggest that the interventions used in Figure 2 . Cost-effectiveness (cost per QALY) of the Enhanced Brief Lifestyle Counseling (EBLC) and Brief Lifestyle Counseling (BLC) interventions, relative to Usual Care (UC). The figure shows the bootstrap distributions of the difference in costs and QALYs and point estimates and 95% confidence intervals (CIs) for the cost-effectiveness ratio (difference in costs [intervention costs þ health-care costs] divided by difference in QALYs). The point estimate (large black circles) for the ratio of cost per QALY indicated that BLC was dominated by UC. The point estimate for EBLC vs UC was $115 397. The 95% CI for BLC vs UC is undefined. The 95% CI for EBLC vs UC includes all values of willingness to pay between the lower limit of $11 568 and the y axis (positive infinity) on the right side of the graph, as well as all values between the upper limit of À $25 084 and the y axis (negative infinity) on the left side of the graph. LL, lower limit; UL, upper limit. 28 ) and from the intervention costs reported in years 1-3 (Herman et al. 19 ). b Cost per kilogram calculated from the reported direct medical program costs (Roux Table 1 ) and an estimated 8.6 kg of weight loss based on changes in BMI (Roux Table 1 ). c Cost per kilograms and per kilogram-year of weight loss calculated from the reported intervention cost (Gustafson Table 3 ) and kilogram lost at 5 months (Gustafson Table 2 ). this clinical trial could be cost-effective over the long term. The primary care setting remains the place where patients with obesity and common weight-and health-related conditions (for example, diabetes, hypertension) are seen and treated the most often. Thus, PCPs have a unique opportunity to initiate obesity treatment and to refer for treatment. Whether on-site treatment, as reimbursed by Medicare, or offsite treatment, as with commercial weight loss programs 50, 51 or call centers, 15 is the most cost-effective way to provide treatment, remains a question for future studies.
In conclusion, we found that a primary care-based intervention of monthly counseling, combined with either meal replacements or pharmacotherapy, was not clearly cost-effective using cost per QALY. However, the intervention appeared reasonably costeffective in the short term using cost per kilogram and in comparison to published estimates.
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